VCA
VRDN icon

Verdence Capital Advisors’s Viridian Therapeutics VRDN Stock Holding History

Verdence Capital Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,879
Closed -$294K – 319
2017
Q4 		$294K Buy
+1,879
New +$239K 0.07% 209

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verdence Capital Advisors's VRDN Position: Q1 2018 in Review

Verdence Capital Advisors sold out of Viridian Therapeutics (VRDN) in Q1 2018, closing a stake of 1,879 shares — an estimated $294K sold.

Verdence Capital Advisors first reported a position in VRDN in Q4 2017 and held it in 1 quarter. The position peaked at $294K in Q4 2017. 59 funds tracked by Wall St. Rank hold VRDN as of Q1 2018.

  • Verdence Capital Advisors reported no remaining Viridian Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Verdence Capital Advisors sold 1,879 Viridian Therapeutics shares in Q1 2018, an estimated $294K.
  • Verdence Capital Advisors first reported a position in Viridian Therapeutics in Q4 2017 and held it in 1 quarter.
  • Verdence Capital Advisors's Viridian Therapeutics position peaked at $294K in Q4 2017.
  • 59 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2018.

Based on Verdence Capital Advisors's 13F filing for Q1 2018, filed 30 Jan 2020.